External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Inflammatory Disease AIBD 2024
Roche and Genentech at

AIBD 2024

December 09 - December 11
Orlando, USA / Virtual (Hybrid)
hmpglobalevents.com
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Dec 11 / Roche and Genentech
RO7790121 as Treatment for Moderate to Severely Active Ulcerative Colitis: Efficacy and First Quality of Life Results from the Phase 2b TUSCANY-2 Trial
Efficacy and first quality-of-life data from the TUSCANY-2 trial. This was a randomised, double-blind, placebo-controlled, dose-ranging Phase 2b study of RO7790121, an antibody against tumour necrosis factor like ligand 1A (anti-TL1A) in adults with moderately to severely active ulcerative colitis.
Inflammatory Disease Inflammatory Bowel Disease AIBD-2024
07:30 PM
Duration 24hrs Orlando, USA
RO7790121 as Treatment for Moderate to Severely Active Ulcerative Colitis: Efficacy and First Quality of Life Results from the Phase 2b TUSCANY-2 Trial
Yarur A, Allegretti JR, Feagan B, Danese S, Schreiber S, Peyrin-Biroulet L, Kierkus J, Leong RW, Bojic D, Lasch K, Schiffman C, Jairath V
Inflammatory Disease | Inflammatory Bowel Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.